We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

177 hedge funds and large institutions have $592M invested in Meridian Bioscience Inc in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 62 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

684% more call options, than puts

Call options by funds: $1.31M | Put options by funds: $167K

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

0% more funds holding

Funds holding: 177177 (0)

3% less repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 62

4% less capital invested

Capital invested by funds: $615M → $592M (-$22.8M)

Holders
177
Holders Change
Holders Change %
0%
% of All Funds
4.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
60
Reduced
62
Closed
16
Calls
$1.31M
Puts
$167K
Net Calls
+$1.14M
Net Calls Change
-$704K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$92.8M +$5.08M +327,584 +6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$64.8M +$1.46M +94,180 +2%
BCM
3
Brown Capital Management
Maryland
$54.6M
Renaissance Technologies
4
Renaissance Technologies
New York
$41.7M +$2.63M +169,932 +6%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$28.1M +$905K +58,358 +3%
State Street
6
State Street
Massachusetts
$20.9M +$2.33M +150,149 +12%
Norges Bank
7
Norges Bank
Norway
$18.9M
SFM
8
Systematic Financial Management
New Jersey
$17M +$135K +8,709 +0.8%
PP
9
Prudential plc
United Kingdom
$15.5M
Geode Capital Management
10
Geode Capital Management
Massachusetts
$12.4M +$347K +22,394 +3%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$12.2M +$149K +9,615 +1%
Invesco
12
Invesco
Georgia
$10.1M +$4.24M +273,770 +68%
JP Morgan Chase
13
JP Morgan Chase
New York
$8.72M -$604K -38,953 -6%
Northern Trust
14
Northern Trust
Illinois
$8.62M +$282K +18,165 +3%
Morgan Stanley
15
Morgan Stanley
New York
$7.81M +$2.97M +191,623 +58%
PPA
16
Parametric Portfolio Associates
Washington
$6.61M +$1.27M +81,818 +23%
Charles Schwab
17
Charles Schwab
California
$6.59M -$97.2K -6,269 -1%
AL
18
AJO LP
Pennsylvania
$6.24M +$153K +9,886 +2%
Ameriprise
19
Ameriprise
Minnesota
$6.08M +$671K +43,264 +12%
Wells Fargo
20
Wells Fargo
California
$5.63M +$406K +26,153 +7%
Principal Financial Group
21
Principal Financial Group
Iowa
$5.35M +$195K +12,606 +4%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$5.13M +$990K +63,837 +23%
New York State Common Retirement Fund
23
New York State Common Retirement Fund
New York
$4.88M -$315K -20,311 -6%
Assenagon Asset Management
24
Assenagon Asset Management
Luxembourg
$4.3M +$4.48M +288,670 New
Man Group
25
Man Group
United Kingdom
$4.27M +$70K +4,516 +2%

VIVO Hedge Fund Activity: Q3 2018 in Review

177 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q3 2018, worth a combined $592M — down 3.7% from $615M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VIVO positions and 16 closed out — a net gain of 2 holders — while 60 added to existing stakes and 62 trimmed.

The largest buyer was BlackRock, adding an estimated $5.08M. The largest seller was Millennium Management, cutting an estimated $2.6M.

  • 177 institutional investors held Meridian Bioscience Inc (VIVO) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $592M of Meridian Bioscience Inc stock for Q3 2018, down 3.7% quarter-over-quarter.
  • 18 funds opened new Meridian Bioscience Inc positions in Q3 2018 and 16 closed out, a net change of +2 holders.
  • The largest Meridian Bioscience Inc buyer in Q3 2018 was BlackRock, an estimated $5.08M added.
  • The largest Meridian Bioscience Inc seller in Q3 2018 was Millennium Management, an estimated $2.6M sold.

Based on aggregated 13F filings for Q3 2018.